|
Use of PPV of [18F]FAPI-74 PET to identify FAP expression in gastrointestinal cancers: Results from a prospective multicenter phase 2 study. |
| |
|
No Relationships to Disclose |
| |
|
|
|
Stock and Other Ownership Interests - SOFIE |
| |
|
|
|
Research Funding - United Imaging (Inst) |
Travel, Accommodations, Expenses - GE Healthcare, Perspective Therapeutics, Telix, Clarity |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Advanced Accelerator Applications; Curium Pharma; EXINI Diagnostics; Novartis; Progenics; Radiomedix |
Consulting or Advisory Role - Astellas Pharma; Blue Earth Diagnostics; Curium Pharma; GE Healthcare; Novartis; Nucleus Radiopharma; POINT Biopharma; Radiomedix; Telix Pharmaceuticals |
Speakers' Bureau - Lantheus Medical Imaging; Novartis |
Research Funding - Fusion Pharmaceuticals (Inst); Novartis (Inst); POINT Biopharma (Inst); Progenics (Inst); Telix Pharmaceuticals (Inst) |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Continental Hospitals |
Consulting or Advisory Role - GE Healthcare, Ferronova, UWorld, ClearNote Health |
Research Funding - Sofie Biosciences, Novartis |
Travel, Accommodations, Expenses - Continental Hospitals |
| |
|
Employment - SOFIE Biosciences Inc |
| |
|
|
| |
|
|